-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MHY0hV6Htn2+1r7HFalmTjLQ04vcLN/sQha3WTwMBRc2ASjMzTXQMefHZDLbhyVP
 d3cw4x85FKW2BPQ5kSIe1Q==

<SEC-DOCUMENT>0000927946-03-000145.txt : 20030711
<SEC-HEADER>0000927946-03-000145.hdr.sgml : 20030711
<ACCEPTANCE-DATETIME>20030711172602
ACCESSION NUMBER:		0000927946-03-000145
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20030630
ITEM INFORMATION:		Acquisition or disposition of assets
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20030711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		03784315

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bas8k.htm
<DESCRIPTION>BIOANALYTICAL SYSTEMS, INC. 8K
<TEXT>
<HTML>
<HEAD>
<Title>Bioanalytical Systems, Inc. - Form 8K</title></head>
<BODY>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<b>UNITED STATES</b><br>
<b>SECURITIES AND EXCHANGE COMMISSION</b></FONT><br>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<b>Washington, D.C. 20549</b></font></P>
<br>

<hr width=30% noshade>

<p align=center><FONT FACE="Times New Roman, Times, Serif" size=4>
<b>FORM 8-K</b><BR><br>
<B>CURRENT REPORT</B><BR><br>
<b><small>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</small></b>
</font></p>
<hr width=30% noshade>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
Date of Report (Date of earliest event reported):&nbsp;&nbsp;<b>June 30, 2003</b>
</font></p>
<br>
<br>
<br>
<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=4>
<b><u>BIOANALYTICAL SYSTEMS, INC.</u></b><br>
<small><small><small>(Exact name of registrant as specified in its charter)</small></small></small>
</font></P>

<table width=95% border=0>
<tr valign=bottom><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u><B>Indiana</B></u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
<B>0-23357</B></u></font></td>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><u>
<B>35-1345024</B></u></font></td></TR>

<TR VALIGN=TOP>
<TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(State or other jurisdiction of<br>incorporation or organization)</font></TD>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Commission File Number)</font></td>
<td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(IRS Employer Identification No.)</font></td></TR>
<tr><TD><br></TD></tr>

<TR VALIGN=bottom><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<B>2701 Kent Avenue</B><br>
<u><B>West Lafayette, IN</B></u></font></TD>
<TD></TD> <td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3><br>
<u><B>47906-1382</B></u></font></td></TR>
<TR VALIGN=top><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Address of principal executive offices)</font></TD><TD>
</TD><td align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Zip Code)</font></td></TR>
<tr><TD></TD></tr>
<TR VALIGN=top><TD> </TD><TD align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
<u><B>(765) 463-4527</B></u></font></TD></TR>
<TR VALIGN=top><TD> </TD><TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=1>
(Registrant's telephone number, including area code)</font></TD></TR>
</TABLE>

<PAGE>

<!-- MARKER FORMAT-SHEET="Head Left" FSL="Default" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 2. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Date and Manner of Acquisition</U> </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On June 30, 2003, PI Acquisition Corp., a wholly-owned subsidiary of
Bioanalytical Systems, Inc. (the &#147;Registrant&#148;), merged with and into
PharmaKinetics Laboratories, Inc. (&#147;PKLB&#148;). As a result of this
merger, PKLB became a wholly-owned subsidiary of the Registrant. Prior to the
merger, on May 26, 2003, the Registrant had converted a Secured Convertible
Revolving Note issued by PKLB to the Registrant into 4,992,300 shares of PKLB
common stock. This conversion resulted in the Registrant owning approximately
67% of the shares of PKLB common stock outstanding at the time of the
merger.</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Assets Acquired</U> </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As a result of the merger, the Registrant acquired all of the assets of PKLB.
These assets consist primarily of real estate, equipment, accounts receivable
and other current assets. PKLB used these assets in the contract research
organization business providing a range of clinical research and development
services to the worldwide pharmaceutical and biotechnology industries in the
development of prescription and non-prescription drug products. The Registrant
intends to continue to use the assets acquired in the merger in the contract
research organization business. The Credit Agreement that the Registrant has
entered into with The Provident Bank requires that the real estate acquired from
PKLB in the merger be sold for its fair market value within 180 days of the
closing of the merger.</FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Workstation" -->
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Consideration</U> </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pursuant to the merger:</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 1- TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT WIDTH=5%>&nbsp;</TD>
<TD WIDTH=95%><div align=justify><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
each holder of PKLB common shares (other than the Registrant) is entitled to
receive one-twelfth (1/12) of one common share of the Registrant for each share
of PKLB common stock they held as of the effective date of the merger; </FONT></div></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 1- TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT WIDTH=5%>&nbsp;</TD>
<TD WIDTH=95%><div align=justify><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
each holder of PKLB Class B Convertible Preferred Stock is entitled to receive
one-twelfth (1/12) of one common share of the Registrant for each share of PKLB
common stock into which their shares of Class B Convertible Preferred Stock were
convertible as of the effective date of the merger. Each share of Class B
Convertible Preferred Stock was convertible into 1.00062 shares of PKLB common
stock as of the effective date of the merger; and </FONT></div></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 1- TNR" FSL="Workstation" -->
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR VALIGN=TOP>
<TD ALIGN=RIGHT WIDTH=5%></TD>
<TD WIDTH=95%><div align=justify><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
each holder of PKLB Class A Convertible Preferred Stock is entitled to receive a
6% Subordinated Convertible Note due 2009 issued by the Registrant with a
principal amount equal to $4.80 per share of Class A Convertible Preferred
Stock. </FONT></div></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Holders of PKLB common stock and Class B Convertible Preferred Stock will
receive a total of approximately 228,857 common shares of the Registrant. The
closing price of the common shares of the Registrant on June 30, 2003 was $2.80.
The aggregate principal amount of the 6% Subordinated Convertible Note due 2009
issued by the Registrant is $3,999,840. The notes are convertible into common
shares of the Registrant at any time after one year after the date of issuance
at a price of $16.00 per share. If all of the notes are converted on the first
anniversary of their issuance, the Registrant would issue approximately 249,990
additional common shares to PKLB shareholders in connection with the
merger.</FONT></P>

<PAGE>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The determination of the amount of consideration set forth above was based upon
several considerations, including the average weighted share values of both PKLB
and the Registrant, the value of the assets of PKLB, and the continuing decline
in the value of PKLB common shares.</FONT></P>

<P align=justify><FONT FACE="Times New Roman, Times, Serif" size=2>
Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</font></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 0- TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Financial Statements of Businesses Acquired: The information required by this
item has been previously filed as part of the Registrant&#146;s Registration
Statement on Form S-4, Registration No. 333-99593.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 0- TNR" FSL="Workstation" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pro Forma Financial Information: The information required by this item has been
previously filed as part of the Registrant&#146;s Registration Statement on Form
S-4, Registration No. 333-99593.</FONT></P>

<!-- MARKER FORMAT-SHEET="Para (List) Indent Lv 0- TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exhibits</FONT></P>

<!-- MARKER FORMAT-SHEET="Exhibit Header" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=BOTTOM>
<TH WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item Number<BR>
assigned in<BR>
<U>Regulation S-K</U>
</FONT></TH>
<TH WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit</U></FONT></TH>
<TH WIDTH=65%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description of Exhibits</U>
</FONT></TH>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2      </FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2.1      </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Agreement and Plan of Merger, dated as of June 20, 2002, among Bioanalytical
Systems, Inc., PI Acquisition Corp. and PharmaKinetics Laboratories, Inc.,
amended and restated to give effect to Amendment No. 1 to Agreement and Plan of
Merger, dated as of July 24, 2002 (incorporated by reference to the Registrant's
Form S-4 filed September 13, 2002).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp; </FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2.2 </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Amendment No. 2 to the Agreement and Plan of Merger dated as of November 21,
2002, by and among PharmaKinetics Laboratories, Inc., Bioanalytical Systems,
Inc. and PI Acquisition Corp., dated as of June 20, 2002, as amended by a first
Amendment, dated as of July 24, 2002 (incorporated by reference to the
Registrant's Current Report on Form 8-K filed November 21, 2002).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp; </FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2.3 </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Amendment No. 3 to the Agreement and Plan of Merger dated as of November 21,
2002, by and among PharmaKinetics Laboratories, Inc., Bioanalytical Systems,
Inc. and PI Acquisition Corp., dated as of April 15, 2003 (incorporated by
reference to the Registrant's Current Report on Form 8-K filed April 16, 2003).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<PAGE>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
4</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
4.1</FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Form of 6% Subordinated Convertible Note due 2008 (incorporated by reference to
BASi&#146;s Current Report on Form 8-K filed November 21, 2002).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp; </FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
4.2</FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Specimen Certificate for Common Shares (incorporated by reference to
4.1 to Registration Statement on Form S-1, Registration No. 333-36429).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>


<PAGE>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>
SIGNATURES </FONT></H1>
<BR>

<!-- MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Default" -->
<P ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</FONT></P>

<!-- MARKER FORMAT-SHEET="Signature Block w/Company Name" FSL="Workstation" -->
<TABLE width=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=60%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
Date:&nbsp;&nbsp;&nbsp;&nbsp;Date:  July 11, 2003</font></TD>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>BIOANALYTICAL SYSTEMS, INC.</U><BR>
<BR>
<BR>
<BR>
By:&nbsp;&nbsp;/s/&nbsp;&nbsp;Douglas P. Wieten<hr>
Douglas P. Wieten<BR>
Vice President &#151; Finance<BR>
Chief Financial Officer and Treasurer</FONT></TD>
</TR>
</TABLE>
<BR>

<PAGE>

<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" size=2>
<B><u>Exhibit Index</u></B></font></P>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit Header" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=BOTTOM>
<TH WIDTH=20%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Item Number<BR>
assigned in<BR>
<U>Regulation S-K</U>
</FONT></TH>
<TH WIDTH=15%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Exhibit</U></FONT></TH>
<TH WIDTH=65%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
<U>Description of Exhibits</U>
</FONT></TH>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2      </FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2.1      </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Agreement and Plan of Merger, dated as of June 20, 2002, among
Bioanalytical Systems, Inc., PI Acquisition Corp. and PharmaKinetics
Laboratories, Inc., amended and restated to give effect to Amendment
No. 1 to Agreement and Plan of Merger, dated as of July 24, 2002
(incorporated by reference to the Registrant's Form S-4 filed September
13, 2002).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2.2      </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Amendment No. 2 to the Agreement and Plan of Merger dated as of November 21,
2002, by and among PharmaKinetics Laboratories, Inc., Bioanalytical Systems,
Inc. and PI Acquisition Corp., dated as of June 20, 2002, as amended by a first
Amendment, dated as of July 24, 2002 (incorporated by reference to the
Registrant's Current Report on Form 8-K filed November 21, 2002).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
&nbsp;</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
2.3      </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Amendment No. 3 to the Agreement and Plan of Merger dated as of November 21,
2002, by and among PharmaKinetics Laboratories, Inc., Bioanalytical Systems,
Inc. and PI Acquisition Corp., dated as of April 15, 2003 (incorporated by
reference to the Registrant's Current Report on Form 8-K filed April 16, 2003).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
4</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
4.1      </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Form of 6% Subordinated Convertible Note due 2008 (incorporated by reference to
BASi&#146;s Current Report on Form 8-K filed November 21, 2002).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

<!-- MARKER FORMAT-SHEET="Exhibit List" FSL="Workstation" -->
<TABLE ALIGN=CENTER WIDTH=80% BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=20%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
</FONT></DIV></TD>
<TD WIDTH=15%><DIV ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
4.2      </FONT></DIV></TD>
<TD WIDTH=65%><DIV ALIGN=JUSTIFY><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
Specimen Certificate for Common Shares (incorporated by reference to Exhibit 4.1
to Registration Statement on Form S-1, Registration No. 333-36429).
</FONT></DIV></TD>
</TR>
</TABLE>
<BR>

</BODY>
</HTML>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
